You are here: Home: Audio Program Guide: BCU Think Tank 2 | 2006 Audio: BCU Think Tank 2 | 2006
 

 
  Go to Section 1
Go to Section 2
Go to Section 3
Go to Section 4
Go to Section 5
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


Section 1:

Incorporation of Bevacizumab into the Treatment of Breast Cancer
   Click here to download the entire section  
Track 1 Introduction
Track 2 Anti-angiogenic therapy in the treatment of breast cancer
Track 3 Clinical use of bevacizumab for patients with metastatic breast cancer
Track 4 Clinical trials of bevacizumab in the adjuvant and neoadjuvant settings
Track 5 Selection of a chemotherapeutic regimen to combine with bevacizumab
Track 6 Bevacizumab combined with trastuzumab for patients with HER2-positive disease

Track 7 Bevacizumab in combination with capecitabine
Track 8 Potential synergy between bevacizumab and endocrine therapy
Track 9 Efficacy and tolerability of metronomic chemotherapy combined with bevacizumab
Track 10 Potential biologic rationale for combining bevacizumab and hormonal therapy
Track 11 Potential role of metronomic chemotherapy in combination with biologic agents
Track 12 Use of bevacizumab for patients with brain metastases

Section 2:

Utility of the OncotypeDX™  Assay in Predicting Benefit of Adjuvant Chemotherapy
   Click here to download the entire section  
Track 1 Utility of the Oncotype DX™ assay in predicting benefit of adjuvant chemotherapy
Track 2 Benefits and limitations of the Oncotype DX assay
Track 3 Use of the Oncotype DX assay in clinical practice
Track 4 Reliability of the Oncotype DX assay versus traditional predictive factors
Track 5 Case-controlled Kaiser Permanente study evaluating the Oncotype DX assay
Track 6 Impact of other predictive factors on Oncotype DX recurrence score

Track 7 Oncotype DX assay for patients with HER2-positive tumors
Track 8 Development of the prognostic algorithm used with Oncotype DX

Section 3:

Optimizing Adjuvant Chemotherapy
   Click here to download the entire section  
Track 1 Paclitaxel- versus docetaxel-based regimens in the adjuvant setting
Track 2 Benefit of adjuvant chemotherapy for patients with ER-positive disease
Track 3 Selection of an adjuvant chemotherapeutic regimen
Track 4 Impact of ER status on sensitivity to chemotherapy
Track 5 Toxicities observed in NSABP-B-38: A Phase III trial comparing TAC to two dose-dense paclitaxel-based regimens
Track 6 CALGB-9344: Impact of adjuvant paclitaxel based on ER and HER2 status

Track 7 Benefit of adjuvant chemotherapy for elderly patients
Track 8 Side effects and tolerability of dose-dense chemotherapy
Track 9 Risk of treatment-related leukemia and myelodysplasia for elderly patients receiving adjuvant chemotherapy
Track 10 Rationale for difficulty enrolling elderly patients in clinical trials
Track 11 Factors affecting the risk of febrile neutropenia with chemotherapeutic regimens
Track 12 Clinical guidelines on the use of prophylactic growth factor support
Track 13 Acceptable risk threshold for febrile neutropenia
Track 14 Prophylactic antibiotics to prevent febrile neutropenia

Section 4:

Cardiac Toxicity Associated with Anthracycline-Based Chemotherapy (Nonanthracycline Alternatives)
   Click here to download the entire section  
Track 1 Increased incidence of cardiac toxicity among patients receiving anthracycline-based chemotherapy
Track 2 Effect of LVEF changes on the risk of congestive heart failure
Track 3 Counseling patients about cardiac risk associated with anthracycline-based chemotherapy
Track 4 Potential rationale for difficulties defining congestive heart failure
Track 5 Clinical use of adjuvant doxorubicin/cyclophosphamide (AC) versus docetaxel/cyclophosphamide (TC)
Track 6 Potential benefits of adjuvant chemotherapy with TC versus AC


Section 5:

Treatment of HER2-Positive Disease
   Click here to download the entire section  
Track 1 HERA trial and the risk of recurrence after one year of trastuzumab therapy
Track 2 Optimal duration of treatment with adjuvant trastuzumab
Track 3 Synergy between trastuzumab and chemotherapeutic agents
Track 4 Clinical use of adjuvant trastuzumab monotherapy
Track 5 Response to trastuzumab in tumors with cMYC and HER2 coamplification
Track 6 Potential utility of TOPO II overexpression in clinical decision-making

Track 7 Lapatinib in the treatment of patients with HER2-positive metastatic breast cancer
Track 8 Implications of the lapatinib data for future clinical research
Track 9 Time to progression as an endpoint in clinical trials
Track 10 Continuation of anti-HER2 agents after progression on trastuzumab
Track 11 Management of HER2-positive disease that progresses on adjuvant trastuzumab
Track 12 Ongoing and future trials for patients with HER2-positive breast cancer